Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a research report issued on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 target price on shares of Trevena in a research report on Thursday, November 14th.

Trevena Price Performance

NASDAQ:TRVN opened at $1.81 on Friday. The company has a market capitalization of $1.56 million, a PE ratio of -0.04 and a beta of 1.08. Trevena has a 52-week low of $1.13 and a 52-week high of $17.50. The stock’s 50 day moving average price is $1.71 and its 200 day moving average price is $2.71.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.